Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease

📖 Top 20% JournalJul 8, 2025Open heart

Semaglutide's impact on survival in people with type 2 diabetes and chronic kidney disease

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

The 3-year risk of all-cause death was 7.2% in patients using semaglutide compared to 9.5% in those using sitagliptin.

Semaglutide is associated with a significantly lower risk of all-cause death in patients with type 2 diabetes and chronic kidney disease compared to sitagliptin.
The incidence of acute heart failure was also lower in the semaglutide group at 12.1% versus 13.1% in the sitagliptin group.
No significant differences were observed between the two groups regarding the risk of acute myocardial infarction and stroke.

AI simplified

BACKGROUND: Type 2 diabetes (T2D) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular events, including death and heart failure (HF). The FLOW trial demonstrated that semaglutide reduces all-cause death, cardiovascular events and HF risk in patients with T2D and CKD. Since there is a difference in patient characteristics between clinical trials and real-world data, this study aims to investigate the association of semaglutide and all-cause death, acute HF or cardiovascular outcomes in patients with T2D and CKD using the data platform.

METHODS: This multicentre retrospective observational study using TriNetX, a global healthcare data platform. We identified 1 151 750 patients aged ≥18 years with T2D and CKD diagnosed before 31 December 2020. Among these, 14 511 patients initiated semaglutide and 69 700 initiated sitagliptin between 1 January 2018 and 31 December 2020. After propensity score matching, 13 703 patients were included in each group. The primary outcome was the 3-year incidence of all-cause death. Secondary outcomes included acute HF, acute myocardial infarction and stroke.

RESULTS: The 3-year risk of all-cause death in the semaglutide group relative to the sitagliptin group was significantly lower (7.2% (943/13 703) vs 9.5% (1196/13 703); p<0.001; HR, 0.76; 95% CI, 0.70 to 0.83). Similarly, the semaglutide group was less likely to have acute HF (12.1% vs 13.1%; HR, 0.92; 95% CI, 0.86 to 0.98). However, the risks of acute myocardial infarction and stroke in the semaglutide group relative to the sitagliptin group were not significant (9.6% vs 9.5%; HR, 1.01; 95% CI, 0.93 to 1.09 in acute myocardial infarction, and 9.2% vs 9.0%; HR, 1.02; 95% CI, 0.94 to 1.10 in stroke).

CONCLUSIONS: In patients with T2D and CKD, semaglutide was associated with a lower 3-year risk of all-cause death compared with sitagliptin.

Key numbers

7.2% vs 9.5%

Decrease in Risk

3-year cumulative incidence in vs. groups

12.1% vs 13.1%

Lower Incidence

3-year cumulative incidence in vs. groups

0.76

Hazard Ratio for

Hazard ratio comparing to

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Abstract

Key numbers

Full Text

Related papers